A Phase 3 interventional study of Iloperidone and Iloperidone Placebo in Bipolar I Disorder, sponsored by Vanda Pharmaceuticals. Completed at 27 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-04-18.
Sponsored by Vanda Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of this study is to investigate the efficacy, safety, and tolerability of iloperidone compared with placebo in treating acute manic or mixed episodes associated with Bipolar I Disorder.
Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Iloperidone
Drug: Iloperidone Placebo
Oral iloperidone
Also known as: FANAPT®, VYV-683
Oral placebo
Change From Baseline to Week 4 in Young Mania Rating Scale (YMRS) Total Score
The Young Mania Rating Scale (YMRS) is an 11-item scale. Individual item scores are summed for a total possible score of 0 (best) to 60 (worst).
Time frame: Week 4
| Milestone | Iloperidone | Placebo |
|---|---|---|
| Started | 206 | 208 |
| Completed | 139 | 153 |
| Not completed | 67 | 55 |
The Young Mania Rating Scale (YMRS) is an 11-item scale. Individual item scores are summed for a total possible score of 0 (best) to 60 (worst).
| Change from Baseline in YMRS Total Score | Iloperidone | Placebo |
|---|---|---|
| Change From Baseline to Week 4 in Young Mania Rating Scale (YMRS) Total Score | -14.0 ± 0.64 | -10.0 ± 0.63 |
Collected over AE data was collected during the 28 day study period plus a 7 day follow up period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Iloperidone | 0/206 (0%) | 4/206 (1.9%) | 88/206 (42.7%) |
| Placebo | 0/208 (0%) | 1/208 (0.5%) | 25/208 (12%) |
| Event | Iloperidone | Placebo |
|---|---|---|
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/206 | 0/208 |
| SedationNervous system disorders | 1/206 | 0/208 |
| Spontaneous penile erectionReproductive system and breast disorders | 1/206 | 0/208 |
| Respiratory distressRespiratory, thoracic and mediastinal disorders | 1/206 | 0/208 |
| Bipolar disorder (depression)Psychiatric disorders | 0/206 | 1/208 |
| Event | Iloperidone | Placebo |
|---|---|---|
| TachycardiaCardiac disorders | 36/206 | 11/208 |
| DizzinessNervous system disorders | 23/206 | 2/208 |
| Dry mouthGastrointestinal disorders | 19/206 | 4/208 |
| Alanine aminotransferase increasedInvestigations | 15/206 | 1/208 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 13/206 | 3/208 |
| Weight increasedInvestigations | 12/206 | 3/208 |
| SomnolenceNervous system disorders | 11/206 | 4/208 |
| Age, Continuous(years) | Iloperidone | Placebo | Total |
|---|---|---|---|
| Mean | 42.9 ± 12.76 | 43.9 ± 12.55 | 43.4 ± 12.65 |
| Sex: Female, Male(Participants) | Iloperidone | Placebo | Total |
|---|---|---|---|
| Female | 90 | 96 | 186 |
| Male | 116 | 112 | 228 |
| Race/Ethnicity, Customized(Participants) | Iloperidone | Placebo | Total |
|---|---|---|---|
| White | 133 | 132 | 265 |
| Black or African American | 62 | 55 | 117 |
| Asian | 0 | 3 | 3 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| American Indian or Alaska Native | 1 | 3 | 4 |
| Other | 9 | 15 | 24 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2021 to primary completion in Sep 2022, 17 months.
Results were first posted in Apr 2024, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iloperidone